Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Recruiting No phase listed Observational

The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support

NCT07532954
View directory record Official record
Conditions
Neuroendocrine Cervical Cancer, Patient Support
Interventions
Questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 4 Interventional Results available

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2, Ipilimumab
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 16, 2026, 8:47 PM EDT
Recruiting Phase 2 Interventional

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

NCT05674396
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Stereotactic body radiotherapy, Traditional Palliation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 1 Interventional

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

NCT00074750
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions
DTGM
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 16, 2026, 8:47 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Thermal Signature of Patients Undergoing Radiation Therapy

NCT00508313
View directory record Official record
Conditions
Lung Cancer
Interventions
Thermal Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 16, 2026, 8:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spousal Relationships and Pain in Metastatic Breast Cancer

NCT00386620
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaire, Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 16, 2026, 8:47 PM EDT
Completed No phase listed Observational

Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00459524
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Questionnaire, Neurocognitive Testing
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

NCT00283582
View directory record Official record
Conditions
Sarcoma
Interventions
rhTPO
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 16, 2026, 8:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

NCT00829959
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 8:47 PM EDT
Completed No phase listed Observational

Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection

NCT00508170
View directory record Official record
Conditions
Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus Infection
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 8:47 PM EDT
Not yet recruiting Not applicable Interventional

Facilitators and Barriers to Cancer Treatment Among Texas Residents

NCT07105046
View directory record Official record
Conditions
Cancer
Interventions
Interviews, Focus Groups
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Withdrawn No phase listed Observational

Cost Utility Analysis in Recurrent Ovarian Cancer

NCT00813254
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Neoadjuvant in Inflammatory Breast Cancer

NCT00756470
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU), Epirubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 16, 2026, 8:47 PM EDT
Active, not recruiting Phase 2 Interventional

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

NCT02152254
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

NCT00038051
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Disorders, Anemia, Refractory, With Excess of Blasts
Interventions
Hum-195/rGel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 16, 2026, 8:47 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

NCT05675579
View directory record Official record
Conditions
Breast Cancer
Interventions
Sacituzumab Govitecan, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

CD19-Specific T Cells Post AlloSCT

NCT03579888
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Ph-Like Acute Lymphoblastic Leukemia, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

CFAR Study in Patients With Chronic Lymphocytic Leukemia

NCT00525603
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia
Interventions
Cyclophosphamide, Fludarabine, Alemtuzumab, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Early Phase 1 Interventional

Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer

NCT02295956
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Questionnaires, Exercise, Nutrition Counseling, Phone Calls, Booklet
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Results available

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

NCT05059470
View directory record Official record
Conditions
Thyroid
Interventions
Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 16, 2026, 8:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

NCT00822770
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia
Interventions
Plerixafor, Filgrastim, Fludarabine, Busulfan, Allogeneic blood stem cell transplant, ATG (Thymoglobulin)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 16, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

NCT02478320
View directory record Official record
Conditions
Advanced Cancers
Interventions
Ilorasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 16, 2026, 8:47 PM EDT